Beeline Medicines has unveiled detailed data behind its Bristol Myers Squibb (BMS)- licenced drug afimetoran, which showed it provided statistically significant benefit at all three doses in a Phase II systemic lupus erythematosus (SLE) trial.
Beeline announced the Phase II trial (NCT04895696) met its primary endpoint in September 2026, with detailed results now showing the degree of clinical benefit. SLE Responder Index-4 (SRI-4) response rates at week 48 were 67.8%, 64.1%, and 66.1% for the 2.5mg, 10mg, and 30mg doses, respectively, compared with 34.4% for placebo. This corresponded to placebo-adjusted differences of between 30.2 and 31.5 percentage points.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Secondary endpoints at the same timepoint were consistent with the primary endpoint, including response rates on the BILAG-based Composite Lupus Assessment (BICLA), which requires improvement in every organ system with moderate or severe activity at baseline, were 38.7-50.8% across afimetoran doses, compared with 27.9% for placebo.
Lupus Low Disease Activity State (LLDAS), which combines low disease activity with a corticosteroid dose of no more than 7.5mg/day, was achieved by 35.6% to 39.1% of afimetoran-treated participants, compared with 21.3% for placebo. In addition, 71.9-75.0% of afimetoran-treated patients reached or maintained a corticosteroid dose of ≤7.5 mg/day, compared with 50.0% for placebo.
Beeline noted this as an important treatment goal in SLE, as long-term corticosteroid exposure is associated with potential cumulative organ damage.
Other secondary endpoints were also met. The company added that afimetoran was generally well tolerated over 48 weeks, with no new safety signals identified across reported adverse events (AEs), laboratory results, or ECG parameters, with most AEs being mild to moderate in severity.
Dr Kenneth Kalunian, professor of medicine at the University of California, San Diego School of Medicine and lead author of the study, said: “In my years of caring for people with lupus, I’ve seen how pain and disease activity can make it hard to work, care for family, or simply get through the day. That is why there is a clear need for well-tolerated and effective oral treatment options. In the Phase II study in SLE, participants treated with afimetoran had substantially higher SRI-4 response rates than placebo at every dose, with consistent improvements in secondary endpoints evaluating skin and joint involvement, symptoms my patients raise at nearly every visit. These results make me optimistic about what an oral TLR7/8 inhibitor could potentially offer, and I’m glad to share them with the lupus community today.”
Following the Phase II data readout, Beeline Medicines plans to advance afimetoran into Phase III development in SLE in 2027 as part of its lupus pivotal development programme. This includes the global Phase II/III DISCOVERY trial in cutaneous lupus erythematosus (CLE) (NCT07881120).
Afimetoran is an investigational oral, once-daily, equipotent inhibitor of Toll-like receptors 7 and 8 (TLR7 and TLR8), which BMS licensed to Beeline in July 2025. The licence came after BMS and Bain Capital formed a new, independent company, which is now operating as Beeline Medicines, to develop five BMS immunology assets, with afimetoran as the lead candidate.
GlobalData forecasts the combined SLE and Lupus Nephritis market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) to reach $5.9bn by 2034. GlobalData is the parent company of Clinical Trials Arena.
Other drugs to watch in this space include AbbVie’s JAK inhibitor Rinvoq (upadacitinib), Biogen’s blood dendritic cell antigen 2 (BDCA2) receptor agonist, litifilimab, and BMS’s Sotyktu (deucravacitinib), according to experts.
